Edition:
United Kingdom

Selecta Biosciences Inc (SELB.OQ)

SELB.OQ on NASDAQ Stock Exchange Global Market

8.94USD
23 Feb 2018
Change (% chg)

$0.29 (+3.35%)
Prev Close
$8.65
Open
$8.75
Day's High
$8.94
Day's Low
$8.56
Volume
36,126
Avg. Vol
83,007
52-wk High
$24.00
52-wk Low
$8.00

Chart for

About

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of... (more)

Overall

Beta: --
Market Cap(Mil.): $435.97
Shares Outstanding(Mil.): 22.07
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018

* SELECTA BIOSCIENCES SAYS EXPECTS TO REPORT INITIAL RESULTS FOR PHASE 2 CLINICAL TRIAL OF SEL-212 IN CHRONIC SEVERE GOUT IN APRIL 2018 - SEC FILING

08 Jan 2018

BRIEF-Selecta Biosciences Says CEO Werner Cautreels Plans Retirement at 2018 End

* SELECTA BIOSCIENCES ANNOUNCES CEO’S INTENT TO RETIRE AND TRANSITION PLAN

02 Jan 2018

BRIEF-Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy

* SELECTA BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LMB-100 AND SVP-RAPAMYCIN COMBINATION THERAPY

02 Jan 2018

BRIEF-Selecta Biosciences announces Q3 loss per share $0.66

* Selecta Biosciences announces third quarter 2017 financial results and provides corporate update

07 Nov 2017

BRIEF-Selecta Biosciences names John Leaman chief financial officer

* Selecta Biosciences announces important additions to senior leadership team

26 Oct 2017

Competitors

Earnings vs. Estimates